Vanguard Group
CRSP icon

Vanguard Group’s CRISPR Therapeutics CRSP Stock Holding History

Vanguard Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$119M Sell
2,268,394
-96,251
-4% -$5.76M ﹤0.01% 1802
2025
Q3 		$153M Buy
2,364,645
+66,556
+3% +$3.82M ﹤0.01% 1680
2025
Q2 		$112M Buy
2,298,089
+528,380
+30% +$20.4M ﹤0.01% 1788
2025
Q1 		$60.2M Buy
1,769,709
+33,711
+2% +$1.43M ﹤0.01% 2017
2024
Q4 		$68.3M Buy
1,735,998
+10,579
+0.6% +$500K ﹤0.01% 2029
2024
Q3 		$81.1M Sell
1,725,419
-23,094
-1% -$1.17M ﹤0.01% 1973
2024
Q2 		$94.4M Buy
1,748,513
+111,714
+7% +$6.46M ﹤0.01% 1858
2024
Q1 		$112M Buy
1,636,799
+46,148
+3% +$3.3M ﹤0.01% 1807
2023
Q4 		$99.6M Buy
1,590,651
+51,926
+3% +$2.87M ﹤0.01% 1865
2023
Q3 		$69.8M Buy
1,538,725
+7,635
+0.5% +$394K ﹤0.01% 1978
2023
Q2 		$86M Buy
1,531,090
+46,521
+3% +$2.64M ﹤0.01% 1934
2023
Q1 		$67.1M Buy
1,484,569
+42,292
+3% +$2.05M ﹤0.01% 2031
2022
Q4 		$58.6M Buy
1,442,277
+6,867
+0.5% +$364K ﹤0.01% 2105
2022
Q3 		$93.8M Buy
1,435,410
+112,269
+8% +$8.14M ﹤0.01% 1825
2022
Q2 		$80.4M Buy
1,323,141
+105,852
+9% +$6.22M ﹤0.01% 1946
2022
Q1 		$76.4M Buy
1,217,289
+880,463
+261% +$55.3M ﹤0.01% 2086
2021
Q4 		$25.5M Sell
336,826
-23,715
-7% -$2.07M ﹤0.01% 2710
2021
Q3 		$40.4M Buy
360,541
+96,783
+37% +$12.2M ﹤0.01% 2480
2021
Q2 		$42.7M Buy
263,758
+4,061
+2% +$494K ﹤0.01% 2455
2021
Q1 		$31.6M Buy
259,697
+9,557
+4% +$1.44M ﹤0.01% 2562
2020
Q4 		$38.3M Sell
250,140
-140,284
-36% -$16.6M ﹤0.01% 2338
2020
Q3 		$32.7M Buy
390,424
+56,870
+17% +$5.04M ﹤0.01% 2234
2020
Q2 		$24.5M Buy
333,554
+147,782
+80% +$8.64M ﹤0.01% 2323
2020
Q1 		$7.88M Buy
185,772
+15,637
+9% +$807K ﹤0.01% 2727
2019
Q4 		$10.4M Buy
170,135
+88,044
+107% +$4.81M ﹤0.01% 2842
2019
Q3 		$3.37M Buy
82,091
+932
+1% +$44.5K ﹤0.01% 3276
2019
Q2 		$3.82M Buy
81,159
+16,821
+26% +$672K ﹤0.01% 3262
2019
Q1 		$2.3M Buy
64,338
+4,283
+7% +$148K ﹤0.01% 3400
2018
Q4 		$1.72M Buy
60,055
+8,032
+15% +$279K ﹤0.01% 3420
2018
Q3 		$2.31M Buy
52,023
+3,200
+7% +$168K ﹤0.01% 3478
2018
Q2 		$2.87M Buy
48,823
+7,479
+18% +$426K ﹤0.01% 3392
2018
Q1 		$1.89M Buy
41,344
+24,076
+139% +$994K ﹤0.01% 3474
2017
Q4 		$405K Sell
17,268
-15
-0.1% -$285 ﹤0.01% 3795
2017
Q3 		$309K Buy
17,283
+264
+2% +$4.79K ﹤0.01% 3837
2017
Q2 		$273K Buy
+17,019
New +$281K ﹤0.01% 3846

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
GP
GSK plc London $599M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Vanguard Group's CRSP Position: Q4 2025 in Review

Vanguard Group reduced its CRISPR Therapeutics (CRSP) stake by 4.1% in Q4 2025, selling an estimated $5.76M and leaving 2,268,394 shares worth $119M. The position accounts for ﹤0.01% of the portfolio, ranked #1802.

Vanguard Group first reported a position in CRSP in Q2 2017 and has held it in 35 quarters since. The position peaked at $153M in Q3 2025. 479 funds tracked by Wall St. Rank hold CRSP as of Q4 2025.

  • Vanguard Group held 2,268,394 shares of CRISPR Therapeutics worth $119M as of Q4 2025.
  • Vanguard Group sold 96,251 CRISPR Therapeutics shares in Q4 2025, an estimated $5.76M.
  • CRISPR Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1802 holding.
  • Vanguard Group first reported a position in CRISPR Therapeutics in Q2 2017 and has held it in 35 quarters since.
  • Vanguard Group's CRISPR Therapeutics position peaked at $153M in Q3 2025.
  • 479 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.